Alpha-1 proteinase inhibitor (human) second generation is under clinical development by Kamada Pharmaceuticals and currently in Phase II for Alpha-1 Antitrypsin Deficiency (A1AD). According to GlobalData, Phase II drugs for Alpha-1 Antitrypsin Deficiency (A1AD) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Alpha-1 proteinase inhibitor (human) second generation’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Alpha-1 proteinase inhibitor (human) second generation overview
The drug candidate is under development for the treatment of alpha- antitrypsin deficiency (inherited emphysema). It is administered through inhalation using e-Flow based inhalation device. The drug candidate is a second generation AAT product. The development of drug candidate is based on e-Flow aerosol technology. It was also under development for cystic fibrosis and bronchiectasis.
Kamada Pharmaceuticals overview
Kamada Pharmaceuticals (Kamada) is a biopharmaceutical company. It is developing specialty plasma-derived therapeutics. The company’s product portfolio features critical care pharmaceuticals delivered via injection, infusion, and inhalation, as well as antiserums for treating snake bites. It includes treatments for immune thrombocytopenic purpura (ITP), post-exposure prophylaxis, and intravenous therapy for Alpha-1 Antitrypsin (AAT) deficiency. Kamada is developing a plasma-derived Hyperimmune IgG therapy for COVID-19, an Inhaled AAT program, and is also in early-stage development of recombinant AAT and liquid AAT for organ preservation. The company distributes its products through local health maintenance organizations (HMOs), hospitals, and pharmacies. Kamada is headquartered in Rehovot, Israel.
For a complete picture of Alpha-1 proteinase inhibitor (human) second generation’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
